新型抗生素的设计,这些抗生素与核糖体转移部位结合
Jalal Haddad1, Lakshmi P Kotra, Beatriz Llano-Sotelo
1Department of Chemistry, Institute for Drug Design, Wayne State University, Detroit, MI 48202, USA.
Journal of the American Chemical Society
|March 28, 2002
概括
针对细菌核糖体RNA的新型设计抗生素被合成,并显示出对病原体的增强活性. 这些新化合物克服了现有的氨基糖化物耐药性机制,提供了一种有前途的新型抗菌剂.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 细菌遗传学 细菌遗传学
背景情况:
- 氨基甘油酸抗生素对于治疗细菌感染至关重要.
- 抗生素耐药性,特别是对氨基糖化物耐药性,是全球日益严重的健康威胁.
- 了解aminoglycoside-ribosomal RNA相互作用的结构基础是设计新药的关键.
研究的目的:
- 设计和合成具有改善抗菌活性的新型氨基糖化物化合物.
- 为了克服细菌中现有的氨基糖化物耐药机制.
- 探索基于结构的药物设计原则,用于新型抗生素的开发.
主要方法:
- 使用结晶结构的尼胺结合细菌核糖体RNA (rRNA) A-site.
- 在化学数据库中进行了大规模的计算搜索,寻找适合rRNA结合口袋的化合物.
- 合成了七种新型化合物,并评估了它们与A位点rRNA的结合亲和力.
- 在体外和体外对致病性细菌和耐药性酶进行了抗菌活性评估.
主要成果:
- 所有七种合成的化合物都表现出与A位点rRNA相似的结合,如neamine.
- 这种新型设计抗生素显著增强了对各种病原体的抗菌活性.
- 这些化合物对具有高水平氨基糖化物耐药性的细菌具有很高的疗效.
- 在体外和体内实验证实,这些合成化合物对于关键的氨基糖化物耐药性酶来说是不良的基质.
结论:
- 基于结构的设计方法成功产生了具有强烈抗菌活性的新型氨基甘油酸.
- 设计的化合物有效地规避了常见的氨基糖化物耐药性机制.
- 这一战略为开发下一代抗生素以对抗耐药细菌感染提供了一个有希望的途径.
相关概念视频
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:16Transduction
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome are...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...